Episode 22 Celebrating 25 years of TKIs in CML
Marking a major milestone in chronic myeloid leukemia treatment
- 05-11-2025
- Chronic Myeloid Leukemia
- Podcast
Director, Georgia Cancer Center, Augusta University, Georgia, USA
Senior Clinical Content Manager, Springer Medicine
Tyrosine kinase inhibitors have transformed the treatment of chronic myeloid leukemia, a condition that had limited therapeutic options before.
In this 25th year since the first phase 2 trials of the first TKI, we speak to a researcher and clinician who has been involved since the early days. Dr. Jorge Cortes shares his experience and talks about the impact of these drugs, not only in the treatment of CML but also more widely.
« Previous episode: Episode 21: Moving towards migraine freedom?